Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Corneal Edema
Corneal Defect
Anterior Chamber Inflammation
Ocular Pain
Corneal Staining
Visual Outcome
CME - Cystoid Macular Edema

Interventions

DRUG: Dextenza 0.4Mg Ophthalmic Insert
DRUG: Prednisolone Acetate 1% Oph Susp
DRUG: Prolensa 0.07% Ophthalmic Solution

Sponsor

Nicole Fram M.D.